Pioneering feat in regenerative medicine, the BEES-HAUS cell therapy: Paracrine effect and cell engraftment, together healing urethral stricture. Its simplified version, BHES-HAUS’ results to be presented in AUA 2026

Contributed by: Business Wire

Logo

Business Wire logo

Images

Urethral stricture starts with narrowing of a short segment of urethral lumen. At early stages, it is managed by balloon dilatation or DVIU Urethrotomy. The open urethrotomy wound after dilatation or DVIU has to heal from the edges of the wound, which may take a longer time. In BEES-HAUS cell therapy, the cell transplant having proven successful engraftment, covering the urethrotomy wound, yielding clinical safety and efficacy may be considered to be included in the treatment guidelines after validation. Its simplified version, the BHES-HAUS (Buccal epithelium Hashed and Encapsulated in Scaffold—Hybrid Approach to Urethral Stricture) accomplished in one-go without need for cell culture in a lab, works on similar principles. After long term follow-up, BHES-HAUS minimally invasive approach may be worth combining with DVIU and balloon dilatation, as it may be able to provide longer duration of recurrence-free, good quality of life without need for intermittent self-catheterization.
Urethral stricture starts with narrowing of a short segment of urethral lumen. At early stages, it is managed by balloon dilatation or DVIU Urethrotomy. The open urethrotomy wound after dilatation or DVIU has to heal from the edges of the wound, which may take a longer time. In BEES-HAUS cell therapy, the cell transplant having proven successful engraftment, covering the urethrotomy wound, yielding clinical safety and efficacy may be considered to be included in the treatment guidelines after validation. Its simplified version, the BHES-HAUS (Buccal epithelium Hashed and Encapsulated in Scaffold—Hybrid Approach to Urethral Stricture) accomplished in one-go without need for cell culture in a lab, works on similar principles. After long term follow-up, BHES-HAUS minimally invasive approach may be worth combining with DVIU and balloon dilatation, as it may be able to provide longer duration of recurrence-free, good quality of life without need for intermittent self-catheterization.
Business Wire embedded0

Tags

Health
Surgery
Health Technology
Research
Science
Biotechnology
GN Corporation Co Ltd

More Like This

In 2008, GN Corp initiated research with NCRM, Chennai, Tamil Nadu, India on restoring corneal blindness using buccal tissue epithelial cells. An out of the box idea of Dr. Suryaprakash, Urologist from Hyderabad, India in 2012 to apply buccal (oral) mucosal cells to repair stricture-inflicted male urethra, led to a clinical study, which he presented in NCRM NICHE 2017 in Tokyo, kickstarting a collaboration with Dr. Akio Horiguchi, National Defence Medical College, Japan, as they met in EAU in 2018 (Top right picture). Upon confirming successful cell engraftment in urethral stricture pre-clinical models taking help from the Dept. of Medical Engineering of NDMC between 2018~2023, (Bottom, right picture), now in 2025, clinical application has been initiated in Edogawa Hospital, Tokyo. Main picture: BEES-HAUS team after the first clinical transplant in Edogawa Hospital, Tokyo; Dr.Horiguchi (Centre) with Dr.Shojiro Katoh (President, Edogawa Hospital) standing left to him.

Cell therapy for male urethral stricture: BEES-HAUS clinical application in Edogawa Hospital Japan, reports Dr. Akio Horiguchi in IMORU.

PR Newswire associated0

Novel Technology Transforms Baldness Treatment Using Beard and Body Hair

PR Newswire associated0

Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results, Highlighting the Therapy's Potential for Patients with Hereditary Hemorrhagic Telangiectasia

PK MED Receives €1.5M DeepTech Non-Dilutive Financing From Bpifrance for the Development of a Local Cell-Homing Implant to Enhance Bone Marrow Transplantation

Business Wire logo

World’s First Patients Successfully Treated With Novel Scarcell Therapeutics Therapy Using Gum Cells Designed to Relieve Knee Osteoarthritis

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

PR Newswire associated0

MitoSense Inc. and Uppsala University, in Collaboration with Elliott Mitochondrial Center and Sallie Astor Burdine Breast Foundation, Announce Breakthrough in Mitochondrial Preservation

Bringing together, all stakeholders involved in research on physical, chemical, and biological realms, biomaterials, and tissue engineering systems to develop novel solutions in regenerative medicine has been the major goal and accomplishment of NCRM NICHE, in the past 18 years. Winners and finalists of Fujio Cup Quiz (FCQ), the “FCQ Elites” are qualified to nominate the candidates for the Edogawa NICHE Prize. The inaugural prize in 2018 was awarded to Prof. James E. Till for discovery of stem cells, jointly with Prof. Ernest McCulloch. 2019 prize was awarded to Dr. Steven A. Rosenberg, for his pioneering work in adoptive immunotherapies and in 2020 to Dr. John Craig Venter for his research in synthetic biology and the human genome. NCRM NICHE team is progressing in research on implications of microgravity, synthetic chemical concoctions, and biological response modifiers, on cellular senescence and immune modulation to develop solutions, especially for rare diseases and unmet needs. (Graphic: Business Wire)

Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.